Log in

NASDAQ:KZRKezar Life Sciences Stock Price, Forecast & News

$4.56
-0.18 (-3.80 %)
(As of 08/11/2020 04:00 PM ET)
Add
Compare
Today's Range
$4.54
Now: $4.56
$4.80
50-Day Range
$4.37
MA: $5.04
$5.75
52-Week Range
$2.18
Now: $4.56
$9.79
Volume129,638 shs
Average Volume517,001 shs
Market Capitalization$210.93 million
P/E RatioN/A
Dividend YieldN/A
Beta0.04
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the United States. Its lead product candidate, KZR-616, a selective immunoproteasome inhibitor that is in Phase 1b/2 clinical trials in lupus and lupus nephritis. The company was founded in 2015 and is headquartered in South San Francisco, California.
Read More
Kezar Life Sciences logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.90 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:KZR
CUSIPN/A
CIKN/A
Phone650-822-5600

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$4.08 per share

Profitability

Net Income$-35,090,000.00

Miscellaneous

Employees24
Market Cap$210.93 million
Next Earnings Date11/4/2020 (Estimated)
OptionableNot Optionable
$4.56
-0.18 (-3.80 %)
(As of 08/11/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive KZR News and Ratings via Email

Sign-up to receive the latest news and ratings for KZR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Kezar Life Sciences (NASDAQ:KZR) Frequently Asked Questions

How has Kezar Life Sciences' stock been impacted by COVID-19 (Coronavirus)?

Kezar Life Sciences' stock was trading at $3.99 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, KZR stock has increased by 14.3% and is now trading at $4.56.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Kezar Life Sciences?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kezar Life Sciences in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Kezar Life Sciences
.

When is Kezar Life Sciences' next earnings date?

Kezar Life Sciences is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Kezar Life Sciences
.

How were Kezar Life Sciences' earnings last quarter?

Kezar Life Sciences Inc (NASDAQ:KZR) announced its quarterly earnings data on Wednesday, August, 5th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.04.
View Kezar Life Sciences' earnings history
.

What price target have analysts set for KZR?

4 Wall Street analysts have issued 12-month price objectives for Kezar Life Sciences' stock. Their forecasts range from $12.00 to $18.00. On average, they anticipate Kezar Life Sciences' share price to reach $15.00 in the next twelve months. This suggests a possible upside of 228.9% from the stock's current price.
View analysts' price targets for Kezar Life Sciences
.

Has Kezar Life Sciences been receiving favorable news coverage?

Media coverage about KZR stock has been trending somewhat positive this week, according to InfoTrie. The research group rates the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Kezar Life Sciences earned a coverage optimism score of 1.0 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days.
View the latest news about Kezar Life Sciences
.

Who are some of Kezar Life Sciences' key competitors?

What other stocks do shareholders of Kezar Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kezar Life Sciences investors own include VBI Vaccines (VBIV), Opko Health (OPK), SCYNEXIS (SCYX), Amarin (AMRN), Dynavax Technologies (DVAX), Entasis Therapeutics (ETTX), Fulcrum Therapeutics (FULC), Kadmon (KDMN), Menlo Therapeutics (MNLO) and Pfizer (PFE).

Who are Kezar Life Sciences' key executives?

Kezar Life Sciences' management team includes the following people:
  • Mr. John Fowler, Co-Founder, CEO & Director (Age 47)
  • Dr. Christopher J. Kirk, Co-Founder, Pres, Chief Scientific Officer & Director (Age 47)
  • Dr. Jack Taunton, Co-Founder
  • Mr. Marc L. Belsky, CFO & Sec. (Age 64)
  • Michael Wolfe, Director of Fin. & Operations

When did Kezar Life Sciences IPO?

(KZR) raised $70 million in an IPO on Thursday, June 21st 2018. The company issued 4,700,000 shares at $14.00-$16.00 per share. Jefferies, Cowen, Wells Fargo Securities and William Blair acted as the underwriters for the IPO.

What is Kezar Life Sciences' stock symbol?

Kezar Life Sciences trades on the NASDAQ under the ticker symbol "KZR."

Who are Kezar Life Sciences' major shareholders?

Kezar Life Sciences' stock is owned by many different institutional and retail investors. Top institutional investors include Candriam Luxembourg S.C.A. (1.57%), Monashee Investment Management LLC (0.32%), Bessemer Group Inc. (0.25%), Virtus ETF Advisers LLC (0.19%), Trexquant Investment LP (0.13%) and Russell Investments Group Ltd. (0.04%). Company insiders that own Kezar Life Sciences stock include Christopher J Kirk, Equal Talent Investments Ltd, Franklin M Berger, John Franklin Fowler, Marc Belsky, Middleton Angus, Morningside Venture Investment and Vassiliki Economides.
View institutional ownership trends for Kezar Life Sciences
.

Which major investors are selling Kezar Life Sciences stock?

KZR stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG.
View insider buying and selling activity for Kezar Life Sciences
.

Which major investors are buying Kezar Life Sciences stock?

KZR stock was purchased by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Monashee Investment Management LLC, Bessemer Group Inc., Virtus ETF Advisers LLC, Trexquant Investment LP, and Russell Investments Group Ltd.. Company insiders that have bought Kezar Life Sciences stock in the last two years include Christopher J Kirk, Equal Talent Investments Ltd, Franklin M Berger, John Franklin Fowler, Marc Belsky, Middleton Angus, Morningside Venture Investment, and Vassiliki Economides.
View insider buying and selling activity for Kezar Life Sciences
.

How do I buy shares of Kezar Life Sciences?

Shares of KZR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Kezar Life Sciences' stock price today?

One share of KZR stock can currently be purchased for approximately $4.56.

How big of a company is Kezar Life Sciences?

Kezar Life Sciences has a market capitalization of $210.93 million. The company earns $-35,090,000.00 in net income (profit) each year or ($1.84) on an earnings per share basis. Kezar Life Sciences employs 24 workers across the globe.

What is Kezar Life Sciences' official website?

The official website for Kezar Life Sciences is www.kezarlifesciences.com.

How can I contact Kezar Life Sciences?

Kezar Life Sciences' mailing address is 4000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-822-5600 or via email at [email protected]

This page was last updated on 8/12/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.